The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
If you think the next wave of biopharma disruption will show up first in clinical pipelines or quarterly earnings, you’re looking in the wrong place.
It’s already showing up in how r…

Stop Overstocking Branded Drugs—Before It Becomes a Margin Problem
Branded drug inventory risk doesn’t announce itself. It shows up quietly—then suddenly.
A wholesaler buys inventory expecting stable demand, only to face a wave of unexpected pricing pr…

Big Pharma doesn’t just “plan for the future.” It signals it—quietly—through who it hires, who it stops hiring, and how quickly it reshuffles teams when patent cliffs hit.
If you want to understand workforce shifts in life sciences, don’t start with he…

Biosimilar sourcing isn’t a procurement problem—it’s an IP strategy problem.
If you’re planning a switch from an originator to a biosimilar, the hardest part usually isn’t finding a supplier. It’s timing the switch so you don’t get caught in the crossf…

Pharma has a new playbook—and it’s not always about new science.
In a world where patients are increasingly asked to pay more for less, the industry’s most controversial strategy is quietly taking center stage: repurposed drugs—old molecules with new i…

Pharma recruiting is broken in a very specific way: we keep asking for “the best scientists,” but we don’t ask the right question—who has actually been building the science that matters?
Most hiring teams rely on titles, publications, or a vague sense …

Pharma has a familiar playbook for “new” prices: take an old drug, reframe the story, and sell the premium as progress.
That’s the tension at the heart of Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines—a topic that…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in global pharma—an obscure policy detail that most investors and operators can safely ignore. But the real story is what happens after the footnote: patent filings that quietly map Russia’s next…

Big Pharma doesn’t always “win” in court. Sometimes it just… never lets the case end.
Europe’s divisional patent game—where companies strategically split patent applications to keep disputes alive—has become a quiet but powerful tool to delay final dec…